Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (3): 438-442.doi: 10.3969/j.issn.1673-8225.2012.03.013

Previous Articles     Next Articles

Effect of rosiglitazone on the growth of CD34 modified decellularized vascular scaffold in vivo 

Liu Yu, Zhang Yu-hai, Shi En-yi, Song Lai-chun, Gu Tian-xiang   

  1. Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang  110001, Liaoning Province, China
  • Received:2011-06-06 Revised:2011-08-10 Online:2012-01-15 Published:2012-01-15
  • Contact: Gu Tian-xiang, Doctor, Professor, Chief physician, Doctoral supervisor, Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China cmugtx@sina.com
  • About author:Liu Yu★, Master, Physician, Department of Cardiac Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China anyway911@ sina.com

PDF

361

Abstract:

BACKGROUND: CD34 antibody-modification can promote the re-endothelialization of decellularized vascular scaffold, but it can also increase the intima hyperplasia. Related studies in China confirm that rosiglitazone as a type of peroxisome proliferator activated receptor-γ (PPAR-γ) agonist can inhibit the hyperplasia and migration of smooth muscle cells in vivo and reduce intima hyperplasia in vascular injury region.
OBJECTIVE: To further verify the effect of rosiglitazone as a type of PPAR-γ agonist on the growth of smooth muscle cells and intima hyperplasia after transplantation of CD34 antibody modified decellularized vascular scaffold in vivo.
METHODS: Fresh carotid arteries from rabbits were involved. CD34 antibody was fixed onto the decellularized vascular scaffolds using photochemical coupling to construct modified tissue engineering vascular which were transplanted into the carotid arteries of the experimental rabbits. Oxidation-treated vascular were transplanted into the control group. CD34 antibody modified vascular were transplanted into the CD34 group and rosiglitazone group, besides, the rosiglitazone group were treated with rosiglitazone.
RESULTS AND CONCLUSION: After transplantation of 10 days, there was few endothelial cells in the transplanted vascular of the control group and more endothelial cells in the CD34 group and the rosiglitazone group, and the intima in the CD34 group was thicker than that in the rosiglitazone group. Alpha-smooth muscle actin showed that the smooth muscle cells in the CD34 group are obviously more than that in the rosiglitazone group. At 30 days, the endothelial cells almost overlaid the whole lining endothelium in the CD34 group and the rosiglitazone group, but the number of endothelial cells in the control group was still small. There were much more smooth muscle-like cells and extracellular matrix in the CD34 group. CD34 antibody-modification can promote the re-endothelialization of decellularized vascular, and rosiglitazone can inhibit the hyperplasia of smooth miscle cells and reduce the intima hyperplasia.

CLC Number: